Uric Acid Levels and Endothelial Functions
Clinical Follow-up of Patients With Assessment of Endothelial Dysfunction/Coronary Spasm
3 other identifiers
observational
229
1 country
1
Brief Summary
Uric acid is a risk factor for coronary artery disease (CED) in postmenopausal women but the association with inflammation and coronary microvascular endothelial dysfunction is not well-defined. The aim of this study was to determine the relationship of serum uric acid, inflammatory markers and CED.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1992
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1992
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2016
CompletedFirst Submitted
Initial submission to the registry
August 8, 2016
CompletedFirst Posted
Study publicly available on registry
August 11, 2016
CompletedAugust 11, 2016
August 1, 2016
24.1 years
August 8, 2016
August 8, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum Uric Acid Level
Baseline
Study Arms (2)
Women With CED
All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
Women Without CED
All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
Interventions
The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
Eligibility Criteria
Female patients referred to Mayo Clinic's cardiac care clinic in Rochester, Minnesota.
You may qualify if:
- Referred to Mayo Clinic for cardiac catheterization
- Postmenopausal
You may not qualify if:
- History of percutaneous coronary intervention
- Coronary artery bypass graft surgery
- Unstable angina pectoris
- Valvular heart disease
- Peripheral vascular disease
- Known congestive heart failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
- National Institute on Aging (NIA)collaborator
Study Sites (1)
Mayo Clinic
Rochester, Minnesota, 55905, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Amir Lerman, M.D.
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine
Study Record Dates
First Submitted
August 8, 2016
First Posted
August 11, 2016
Study Start
January 1, 1992
Primary Completion
February 1, 2016
Study Completion
February 1, 2016
Last Updated
August 11, 2016
Record last verified: 2016-08